- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Family History of Pancreas Cancer, Genetic Testing, Multi-cancer Early Detection
- Interventions
- Telephone education session, Online educational materials
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,111
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Vismodegib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
- Interventions
- therapeutic autologous lymphocytes, cyclophosphamide, aldesleukin, polymerase chain reaction, gene rearrangement analysis, lymph node biopsy, genetically engineered lymphocyte therapy, bone marrow aspiration, flow cytometry, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer
- Interventions
- WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim, polymerase chain reaction, flow cytometry, immunoenzyme technique
- Biological · Genetic · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Congenital Myotonic Dystrophy, CDM
- Interventions
- Not listed
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- Up to 59 Months
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Fairway, Kansas • Rochester, New York + 1 more
- Conditions
- Spinal Muscular Atrophy (SMA), Carrier Screening, Genetic Testing
- Interventions
- Blood draw
- Procedure
- Lead sponsor
- Natera, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- San Carlos, California
- Conditions
- Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
- Interventions
- everolimus, erlotinib hydrochloride, biopsy, laboratory biomarker analysis, immunohistochemistry staining method, polyacrylamide gel electrophoresis, pharmacological study, external beam radiation therapy, microarray analysis
- Drug · Procedure · Other + 2 more
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Craniometaphyseal Dysplasia
- Interventions
- Not listed
- Lead sponsor
- UConn Health
- Other
- Eligibility
- Not listed
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2030
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Leiomyosarcoma
- Interventions
- Blood and Tissue collection
- Other
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Rochester, Minnesota • Nashville, Tennessee
- Conditions
- Gastric Cancer
- Interventions
- fluorouracil, leucovorin calcium, oxaliplatin, gene expression analysis, polymorphism analysis, protein expression analysis, pharmacological study
- Drug · Genetic · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 5
- States / cities
- St Louis, Missouri • Chapel Hill, North Carolina • Nashville, Tennessee
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
- Interventions
- Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI)
- Other · Behavioral
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 793 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Head and Neck Cancer
- Interventions
- gene expression analysis, mutation analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, pharmacological study
- Genetic · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Keratoconus, Corneal Ectasia
- Interventions
- Riboflavin 0.1% ophthalmic solution, CCL-VARIO UV lamp, CCL-VARIO at 18 mW/cm2
- Drug · Device
- Lead sponsor
- Robert Mack, M.D.
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Hoffman Estates, Illinois
- Conditions
- Endometrial Cancer
- Interventions
- Surveys
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Not listed
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Sarcoidosis With Myocarditis, Sarcoidosis, Healthy, ST Elevation Myocardial Infarction
- Interventions
- cell free DNA
- Diagnostic Test
- Lead sponsor
- Nabeel Hamzeh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Waldenström Macroglobulinemia
- Interventions
- vorinostat, rituximab, ifosfamide, carboplatin, etoposide, pharmacological study, laboratory biomarker analysis, gene expression analysis
- Drug · Biological · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Rolandic Epilepsy
- Interventions
- Blood draw, Existing samples
- Other
- Lead sponsor
- King's College London
- Other
- Eligibility
- 6 Years to 25 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- New York, New York • Providence, Rhode Island • Seattle, Washington
- Conditions
- Adult Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
- Interventions
- 5-fluoro-2-deoxycytidine, tetrahydrouridine, laboratory biomarker analysis, reverse transcriptase-polymerase chain reaction, DNA methylation analysis
- Drug · Other · Genetic
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Arthroplasty Complications
- Interventions
- Pharmacogenomics Testing
- Diagnostic Test
- Lead sponsor
- Anderson Orthopaedic Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Alexandria, Virginia
- Conditions
- Breast Cancer
- Interventions
- gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, medical chart review, questionnaire administration
- Genetic · Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Candidates for BRCA 1/2 Genetic Testing
- Interventions
- Genetic Providers, Visual Aids, Post-Disclosure Asessments, In-person Clinical Follow-Up, 6 Month and 12 Month Assessments
- Genetic · Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 289 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Camden, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
- Interventions
- Diagnostic Laboratory Biomarker Analysis, Immunohistochemistry Staining Method, Medical Chart Review, Microarray Analysis, Study of Socioeconomic and Demographic Variables, Western Blotting
- Other · Genetic
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- RealRisks
- Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Genetic Testing for Cancer Risk, Liquid Biopsy, Magnetic Resonance Imaging of the Whole Body without Contrast, Survey Administration
- Procedure · Genetic · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California